title: Irreversible protein kinase inhibitors: balancing the benefits and risks.
authors.affiliation: Drug Discovery Unit, Covalution Pharma BV, Ravenstein, The Netherlands. tjeerd.barf@covalution.com
authors.forename: Tjeerd
authors.initials: T
authors.lastname: Barf
authors.forename: Allard
authors.initials: A
authors.lastname: Kaptein
mesh_terms: D000818:Animals; D002460:Cell Line; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D011494:Protein Kinases / Q000737:chemistry / Q000378:metabolism*; D012306:Risk; D013329:Structure-Activity Relationship; D013997:Time Factors
chemical_list: D047428:Protein Kinase Inhibitors; D011494:Protein Kinases